Congress hands pharma a $2B tax break for brain research—no price controls attached

What it does

This bill creates a new federal tax credit worth up to $2 billion per year (2027–2030) for companies and research institutions conducting translational research on neurodegenerative diseases and psychiatric conditions. The credit covers 25% of qualifying research expenses, with allocation decisions made by the Secretary of the Treasury in consultation with HHS, FDA, and NIH based on scientific merit. Tax-exempt entities (universities, nonprofits, government agencies) can transfer their credit to for-profit partners, allowing private companies to claim the tax benefit even when the research is conducted by public institutions.

Why we flagged it

Despite the public-health framing, the bill's core mechanism is a $2 billion annual tax credit that flows primarily to for-profit pharmaceutical and biotech companies. The credit is structured as a business tax incentive, not a direct public research investment or price guarantee.

What the text implies

• Tax-exempt entity credit transfer mechanism allows universities and nonprofits to conduct research at public expense, then transfer the tax benefit to private companies—effectively subsidizing private R&D with public research infrastructure and tax revenue.
• No requirement that treatments developed under this credit be affordable, available to the public, or priced reasonably—companies can use the subsidy to offset R&D costs while charging monopoly prices.
• Allocation criteria emphasize 'public-private partnerships' and 'sharing of intellectual property held by tax exempt entities'—language that may facilitate transfer of publicly-funded discoveries to private ownership.
• Credit sunsets in 2035, creating a time-limited incentive that may accelerate spending in early years but provides no long-term commitment to sustained research funding.
• Regulatory language is delegated to Treasury, HHS, FDA, and NIH—the actual allocation criteria and scientific merit standards are not in statute, reducing congressional oversight and transparency.

Who it affects

The bill may accelerate development of treatments for serious neurological and psychiatric diseases, potentially benefiting patients. However, the primary financial benefit flows to pharmaceutical and biotech companies via a tax subsidy, and the mechanism allows private firms to capture public research value without clear public return guarantees or pricing controls.

Who stands to gain

• pharmaceutical companies (Pfizer, Bristol Myers Squibb, Johnson & Johnson)
• biotech firms
• medical device manufacturers
• contract research organizations

Named in the bill

Pfizer (PFE), Bristol Myers Squibb (BMY), Johnson & Johnson (JNJ), Guardant Health (GH), DaVita (DVA), Internal Revenue Code Section 45BB, Section 38 (general business credit), Treasury Department, HHS, FDA, NIH, tax-exempt entities — and 1 more

Where it stands

7 cosponsors: 6 Democrats, 1 Republicans.

• Mar 11, 2025 — Introduced · Congress.gov: “Introduced in House”
• Mar 11, 2025 — Referred to House Committee on Ways and Means · Congress.gov: “Referred to the House Committee on Ways and Means”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

1 lobbying clients named this bill on 1 disclosure filings across 1 quarter, Dec 2025 to Dec 2025. Those filings disclosed $5,300,000 in lobbying spend. A filing names 104 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 0% of bills with at least one filing.

Mike Thompson, the sponsor, reported $1,956,640 in PAC receipts in the 2026 cycle.

• AARP — $5,300,000 on 1 filing

Lobbying Disclosure Act filings through Jan 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.